Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

Johnson & Johnson Achieves Positive Phase III Results for Nipocalimab in Generalized Myasthenia Gravis

Fineline Cube Jul 1, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US-based healthcare company, has announced positive results...

Company Deals

Hasten Biopharmaceutical Expands into Pan-Asia Regions with Celltrion Asset Acquisition

Fineline Cube Jul 1, 2024

Hasten Biopharmaceutical Co., Ltd, a China-based pharmaceutical company backed by CBC Group, has announced an...

Company Drug

Bio-Thera Solutions’ BAT2094 Wins NMPA Nod for Acute Coronary Syndrome Treatment

Fineline Cube Jul 1, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Drug

Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge

Fineline Cube Jul 1, 2024

Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking...

Company Drug

Luye Pharma’s Manufacturing Facility Passes FDA Inspection for Paliperidone Palmitate Product

Fineline Cube Jun 28, 2024

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that it has successfully...

Company Drug

Sirnaomics’ STP707 Shows Promising Results in Phase I Pancreatic Cancer Trial

Fineline Cube Jun 28, 2024

Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company, has announced the successful completion of a Phase...

Company Deals

Shandong Junxiu Biotechnology Partners with Swiss Firm Geistlich to Boost Regenerative Medicine

Fineline Cube Jun 28, 2024

Shandong Junxiu Biotechnology Co., Ltd, a Chinese manufacturer of implantable regenerative medicine devices, has entered...

Company Drug

Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma

Fineline Cube Jun 28, 2024

Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...

Company Deals

AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

Fineline Cube Jun 28, 2024

AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics...

Company Drug

Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply

Fineline Cube Jun 28, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...

Company Deals

Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology

Fineline Cube Jun 28, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...

Company Drug

Hybio Pharmaceutical Gets FDA Nod for Tirzepatide Raw Materials in DMF Filing

Fineline Cube Jun 28, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Abbisko Therapeutics Presents Positive Phase II Results for HCC Treatment at ESMO-GI

Fineline Cube Jun 28, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotech company, has announced the presentation of...

Company Deals

China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million

Fineline Cube Jun 28, 2024

Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the...

Company Deals

Shanghai Kehua Bioengineering’s Subsidiary to Acquire Remaining Stake in Technogenetics S.P.A.

Fineline Cube Jun 28, 2024

Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a Chinese bioengineering company, has announced that its...

Company Drug

Dizal Pharmaceutical’s Golidocitinib Breaks Record with Rapid Market Launch in China

Fineline Cube Jun 28, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has seen its...

Company Deals

GenScript Biotech Receives Over USD 410 Million in Milestone Payments for CAR-T Therapy from Janssen Biotech

Fineline Cube Jun 28, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Deals

Jianke.com, China’s Leading Chronic Disease Management Platform, Files for Hong Kong IPO

Fineline Cube Jun 28, 2024

Jianke.com, a China-based smart healthcare service platform, has filed for an initial public offering (IPO)...

Company Deals

TowardPi Medical Secures RMB 200 Million in Series D Financing Led by Matrix Partners

Fineline Cube Jun 28, 2024

TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company, has reportedly secured RMB 200...

Company Deals

Amoy Diagnostics Partners with Servier to Develop Companion Diagnostic Reagent for IDH Mutations in China

Fineline Cube Jun 28, 2024

China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has entered into a partnership with French...

Posts pagination

1 … 390 391 392 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.